N2OFF: Save Foods to Target California’s Hemp Market
May 06, 2024 07:13 ET
|
N2OFF Inc.
More than half of US hemp flower grown in California recently received Pre-Harvest Regulatory Approval in California allowing Save Foods to treat hemp Neve Yarak, Israel, May 06, 2024 (GLOBE...
Skyward Specialty Announces Secondary Offering of Its Common Stock
May 06, 2024 07:12 ET
|
Skyward Specialty Insurance Group, Inc.
HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”)...
Flash News: OKX Launches Cryptopedia Season 17 Campaign Featuring 6,666,666 Ultiverse Token Prize Pool
May 06, 2024 07:03 ET
|
OKX
SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- OKX, a leading Web3 technology company, has issued updates for May 6, 2024. OKX Launches Cryptopedia Season 17 Campaign Featuring 6,666,666 Ultiverse...
Stellantis Pro One Achieves No. 1 Spot in Middle East & Africa Region and Strengthens Commercial Vehicle Leadership in Europe and South America
May 06, 2024 07:01 ET
|
STELLANTIS N.V
Stellantis Pro One Achieves No. 1 Spot in Middle East & Africa Region and Strengthens Commercial Vehicle Leadership in Europe and South America Achieves No. 1 spot with a record 26% market share...
BiomX to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 06, 2024 07:00 ET
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 06, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...
AMG Reports Financial and Operating Results for the First Quarter of 2024
May 06, 2024 07:00 ET
|
Affiliated Managers Group, Inc.
Company reports EPS of $4.14, Economic EPS of $5.37 in first quarter Net Income (controlling interest) of $150 million, Economic Net Income (controlling interest) of $187 millionEconomic Earnings per...
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 06, 2024 07:00 ET
|
Omega Therapeutics
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data...
Mikra Announces Joint Product with Jose Bautista
May 06, 2024 07:00 ET
|
Lifeist Wellness Inc.
Lifeist announces FOCUS in partnership with Jose Bautista
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 06, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q...
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
May 06, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no...